A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors.
Miguel A EscobarMichael BullanoAli G MokdadJorge CaicedoBob G SchultzQi FanSumit VermaPublished in: Expert review of hematology (2023)
, suggesting that switching from FVIII to emicizumab may not deliver incremental benefits to PwHA receiving prophylactic care.
Keyphrases